Inhibrx Biosciences, Inc.
Statements
Ratios
Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.1 | 0.1 | 0.1 | 0.1 | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 113.5 | 140.1 | 1,114.6 | 1,082.8 | 158.0 | 372.6 | 941.1 | 805.6 | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.0 | 1.4 | 1.7 | 2.3 | 3.2 | 14.2 | 153.1 | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -7.8 | 27.9 | 359.6 | 503.3 | 97.2 | 336.2 | 924.7 | 817.7 | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.1 | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -113.2% | -87.9% | -88.4% | -77.9% | -63.4% | -27.5% | -10.6% | -12.6% | -8.9% | |
| Margins | ||||||||||||||||||||||||||||||||||
| – | – | – | -313.8% | -56.2% | 10.5% | 68.8% | 113.3% | 86.2% | -269.9% | -276.9% | -203.0% | -331.7% | -248.2% | -140.2% | -147.8% | 71.4% | 60.3% | 40.5% | -30.7% | -90.7% | -238.6% | -266.6% | 33.8% | 29.5% | 48.1% | 18.2% | -804.5% | -962.0% | -99.0% | -86.3% | -91.0% | -80.4% | – | |
| – | – | – | -364.8% | -162.7% | -195.0% | -282.5% | -450.4% | -1,873.6% | -1,168.0% | -621.7% | -526.6% | -534.3% | -681.7% | -1,042.3% | -1,065.9% | -1,202.9% | -1,456.3% | -2,385.1% | -5,928.9% | -11,239.5% | -25,143.2% | -37,825.5% | -12,178.9% | -13,980.9% | -19,905.0% | -21,326.9% | -165,724.0% | -150,262.0% | -11,929.6% | -11,002.1% | -10,386.5% | -9,465.5% | – | |
| – | – | – | -381.7% | -173.2% | -207.0% | -356.1% | -565.3% | -2,306.4% | -1,413.4% | -726.1% | -594.3% | -588.5% | -750.0% | -1,097.9% | -1,138.0% | -1,295.2% | -1,583.6% | -2,760.0% | -6,912.2% | -13,123.8% | -29,600.2% | -42,828.9% | -13,396.4% | -15,207.8% | 88,176.4% | 94,684.7% | 843,786.0% | 861,485.5% | -11,692.4% | -11,077.6% | -10,773.5% | -10,014.2% | – | |
| – | – | – | -403.5% | -202.0% | -321.6% | -262.6% | -372.7% | -1,217.7% | -624.9% | -442.8% | -385.2% | -496.2% | -716.4% | -1,042.8% | -1,130.0% | -1,196.4% | -1,301.6% | -2,278.6% | -5,325.4% | -9,054.0% | -21,913.7% | -35,341.1% | -10,272.1% | -12,456.8% | -12,847.3% | -12,314.5% | -98,503.0% | -84,376.5% | -10,009.5% | -10,245.6% | -9,986.5% | -10,148.8% | – | |
| Returns | ||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | -81.5% | -100.9% | -124.3% | -176.3% | -277.4% | -156.1% | -342.7% | – | – | -259.3% | -1,110.1% | – | -145.4% | -554.3% | -2,344.0% | 744.8% | 920.0% | 1,263.3% | 1,824.4% | -238.8% | -421.1% | -1,752.2% | – | – | |
| – | – | – | -288.7% | -103.1% | -54.4% | – | -194.0% | -434.6% | -349.5% | -52.1% | -53.0% | -60.5% | -55.1% | -60.6% | -54.3% | -58.2% | -57.3% | -79.4% | -51.8% | -66.2% | -83.2% | -50.6% | -78.3% | -94.0% | 632.3% | 737.7% | 933.6% | 710.1% | -77.2% | -87.4% | -95.6% | -70.8% | -89.6% | |
| Balance Sheet & Debt | ||||||||||||||||||||||||||||||||||
| -8.3 | – | – | 3.8 | 2.9 | -20 | – | -6.9 | – | -4.2 | -126 | -127 | -106 | -124 | -111 | -130 | -142 | -175 | -144 | -272 | -232 | -191 | -335 | -276 | -247 | -225 | -194 | -151 | -116 | -85 | -51 | -21 | 16 | 45 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -0.1 | -0.1 | -0.1 | -0.1 | – | – | – | – | – | |
| -166.8% | – | – | -577.4% | -252.2% | -121.6% | – | -353.2% | -340.9% | -90.3% | 63.9% | 52.5% | 48.7% | 31.2% | 21.8% | 34.8% | 17.0% | -2.5% | -21.3% | 20.0% | 6.0% | -11.6% | 34.8% | 14.1% | 4.0% | 84.9% | 80.2% | 73.9% | 38.9% | 32.3% | 20.8% | 5.5% | -11.4% | -34.4% | |
| – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | – | – | 0.0 | 0.1 | – | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 | 0.0 | 1.1 | 1.5 | 2.8 | 12.9 | – | – | |
| Per Share | ||||||||||||||||||||||||||||||||||
| – | – | – | -1.03 | -0.86 | -0.92 | -1.37 | -1.79 | -2.35 | -2.09 | -2.80 | -2.02 | -2.00 | -2.07 | -2.06 | -2.12 | -2.40 | -2.84 | -3.35 | -3.48 | -3.86 | -4.06 | -4.00 | -4.46 | -4.97 | 110.35 | 106.14 | 116.58 | 111.39 | -10.58 | -10.02 | -9.04 | -8.35 | -8.82 | |
| – | – | – | 0.27 | 0.50 | 0.44 | 0.39 | 0.32 | 0.10 | 0.15 | 0.39 | 0.34 | 0.34 | 0.28 | 0.19 | 0.19 | 0.19 | 0.18 | 0.12 | 0.05 | 0.03 | 0.01 | 0.01 | 0.03 | 0.03 | 0.13 | 0.11 | 0.01 | 0.01 | 0.09 | 0.09 | 0.08 | 0.08 | 0.00 | |
| -1.58 | -0.05 | – | -2.06 | -2.10 | -2.06 | – | -3.25 | -1.84 | -0.54 | 3.43 | 2.00 | 1.61 | 1.17 | 0.74 | 1.36 | 0.70 | -0.13 | -0.90 | 1.34 | 0.35 | -0.57 | 2.75 | 0.81 | 0.21 | 14.82 | 11.54 | 9.23 | 6.11 | 4.43 | 2.38 | 0.52 | -1.35 | -3.38 | |
| – | – | – | -1.09 | -1.00 | -1.43 | -1.01 | -1.18 | -1.24 | -0.92 | -1.70 | -1.31 | -1.68 | -1.97 | -1.96 | -2.10 | -2.22 | -2.33 | -2.76 | -2.68 | -2.66 | -3.01 | -3.30 | -3.42 | -4.07 | -16.08 | -13.80 | -13.61 | -10.91 | -9.06 | -9.27 | -8.38 | -8.47 | -8.42 | |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.